(Most of the reform was ultimately abandoned after a series of successful court challenges, of which Novo Nordisk Canada was a party.) Thomas Digby, a B.C.-based intellectual-property lawyer and chair of the review board from 2023 to 2025, said that if its true that Novo abandoned its Ozempic/Wegovy patent in order to avoid PMPRB review, choosing instead to face generic entry, then its completely unprecedented in my experience, and quite possibly a strategic business mistake. Patent protections will lapse in India and Brazil in March, and in China and Turkey later in the year
Efficacy: High doses do not reliably improve hair growth in patients with normal biotin levels
Rafael F, Rodrigues MD, Bellver J, Canelas-Pais M, Garrido N, Garcia-Velasco JA, et al
These medications work by mimicking the effects of the natural GLP-1 hormone in your body
Prepared in licensed, third-party tested compounding pharmacies to strict quality standards